Login to Your Account

Genta, Aventis Begin Rolling NDA Upon Release Of Genasense Data

By Kim Coghill

Thursday, September 11, 2003
Without the benefit of full data on a 771-patient Phase III trial, Wall Street remained a little wary about results released Wednesday by Genta Inc. and partner Aventis SA on Genasense, an antisense oncology compound being studied in malignant melanoma. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription